Deciphera Pharmaceuticals Inc. (DCPH) and ChromaDex Corporation (NASDAQ:CDXC) Comparing side by side

Since Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) and ChromaDex Corporation (NASDAQ:CDXC) are part of the Biotechnology industry, they are influenced by contrast. The influences particularly affect the profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation of both companies.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Deciphera Pharmaceuticals Inc. N/A 0.00 125.81M -2.60 0.00
ChromaDex Corporation 35.04M 7.50 33.21M -0.63 0.00

Table 1 showcases the top-line revenue, earnings per share (EPS) and valuation of Deciphera Pharmaceuticals Inc. and ChromaDex Corporation.

Profitability

Table 2 represents Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) and ChromaDex Corporation (NASDAQ:CDXC)’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Deciphera Pharmaceuticals Inc. 0.00% -35.4% -31.9%
ChromaDex Corporation -94.78% -77.8% -61.9%

Liquidity

Deciphera Pharmaceuticals Inc.’s Current Ratio and Quick Ratio are 18.5 and 18.5 respectively. The Current Ratio and Quick Ratio of its competitor ChromaDex Corporation are 3.2 and 2.7 respectively. Deciphera Pharmaceuticals Inc. therefore has a better chance of paying off short and long-term obligations compared to ChromaDex Corporation.

Analyst Ratings

Deciphera Pharmaceuticals Inc. and ChromaDex Corporation Ratings and Recommendations are available on the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Deciphera Pharmaceuticals Inc. 0 0 1 3.00
ChromaDex Corporation 0 0 0 0.00

Deciphera Pharmaceuticals Inc.’s upside potential currently stands at 113.04% and an $50 consensus price target.

Institutional and Insider Ownership

Institutional investors held 58.5% of Deciphera Pharmaceuticals Inc. shares and 17.7% of ChromaDex Corporation shares. Deciphera Pharmaceuticals Inc.’s share held by insiders are 0.1%. Competitively, insiders own roughly 2.3% of ChromaDex Corporation’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Deciphera Pharmaceuticals Inc. -0.38% 6.59% 12.84% -23.93% 17.57% 36.45%
ChromaDex Corporation -6.93% 4.8% -2.24% -22.96% -33.4% 1.75%

For the past year Deciphera Pharmaceuticals Inc.’s stock price has bigger growth than ChromaDex Corporation.

Summary

Deciphera Pharmaceuticals Inc. beats on 6 of the 10 factors ChromaDex Corporation.

Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company develops DCC-2618, a pan-KIT and pan-PDGFRa inhibitor for the treatment of gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. It is also developing immunokinase inhibitors comprising DCC-3014 for treatment of solid tumors and hematologic malignancies; and Rebastinib to treat breast cancer, as well as to investigate in combination with chemotherapy and checkpoint inhibitors. The company was founded in 2003 and is headquartered in Waltham, Massachusetts.

ChromaDex Corporation, a natural products company, discovers, acquires, develops, and commercializes patented and proprietary ingredient technologies. The company offers bulk raw materials for use in dietary supplements, food, beverages, and cosmetic products; Nicotinamide riboside (NIAGEN), a vitamin found naturally in milk for enhancing cardiovascular health, glucose levels, cognitive function, and anti-aging effects; Pterostilbene (pTeroPure), a polyphenol and antioxidant used in health related fields; and Immulina, a spirulina extract and compound, which is used for improving human immune function, as well as developing Pterostilbene and caffeine co-crystal ingredients, and anthocyanins ingredients. It also provides reference standards, materials, and kits to conduct quality control of raw materials and consumer products; and fine chemicals and phytochemicals for research and new product development applications. In addition, the company offers a range of contract services, including routine contract analysis for the production of dietary supplements, cosmetics, foods, and other natural products, as well as elaborate contract research for clients in these industries; and consulting services in the areas of regulatory support, new ingredient or product development, risk management, and litigation support, as well as product regulatory approval and scientific advisory services. Further, it assists customers in creating processes for manufacturing of natural products using green chemistry, as well as developing quality verification seal program, phytochemical libraries, plant extracts libraries, and databases for cross-referencing phytochemicals. The company markets and sells its products directly in the United States and Canada; and through distributors in Europe, China, Japan, South Korea, Brazil, Australia, New Zealand, Taiwan, South Africa, India, Indonesia, Malaysia, Singapore, Thailand, and Mexico. ChromaDex Corporation is based in Irvine, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.